Glucagon News and Research

RSS

Study shows prediabetes remission does not always require weight loss

Remission of prediabetes can occur even without weight loss, protecting against type 2 diabetes in up to 22% of individuals. Metabolic improvements, healthier fat distribution, and enhanced β-cell function, not body weight change, drive this benefit.

30 Sep 2025

Scientists outline how future therapies could change type 1 diabetes care

Researchers writing in The Lancet review breakthroughs in type 1 diabetes treatment, from immunotherapies that delay onset to stem-cell β-cell replacement and automated insulin delivery. They stress that equitable access, validated surrogate endpoints, and scalable technologies are crucial for lasting impact.

24 Sep 2025

New quintuple agonist shows promise for treating obesity and type 2 diabetes

Much excitement has built in recent years on the new class of incretin drugs that include glucagon-like-peptide-1 inhibitor (single agonists such as semaglutide) and also dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonists (dual agonists such tirzepatide).

21 Sep 2025

Study points to a surprising new ally in the fight against type 2 diabetes

A new study from Duke University School of Medicine is challenging long-standing views on blood sugar regulation - and pointing to a surprising new ally in the fight against type 2 diabetes.

19 Sep 2025

Can eating style affect how well GLP-1 drugs control diabetes and weight?

Research indicates that external eating behavior is a key predictor of weight loss in type 2 diabetes patients receiving GLP-1 receptor agonists.

19 Sep 2025

Daily orforglipron GLP-1 pill achieves over 11% weight loss in global obesity trial

In a phase 3 trial, once-daily oral orforglipron induced significant, dose-dependent weight loss over 72 weeks in adults with obesity but no diabetes. It also improved multiple cardiometabolic markers with a safety profile similar to other GLP-1 receptor agonists.

18 Sep 2025

Scientists unveil new obesity drug that reprograms fat and energy use

Details of a new drug that aims to treat the underlying causes of obesity are being presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Vienna, Austria (15-19 September).

18 Sep 2025

GLP-1RAs linked to lower risk of mortality and cardiovascular events in psoriasis patients

Psoriasis patients treated with glucagon-like peptide-1 receptor agonists (GLP-1RAs) face a 78% lower risk of death and a 44% lower risk of major cardiovascular events compared to those taking other diabetes or weight-loss medications, new research has shown.

17 Sep 2025

A new tool in the fight against obesity: Orforglipron's substantial weight loss results

New research presented at the Annual Meeting of the European Association for the Study of Diabetes in Vienna, Austria (Sept 15-19) and simultaneously published in NEJM shows that daily treatment with the new once-daily GLP-1 agonist orforglipron results in substantial weight loss in people living with obesity that do not have type 2 diabetes.

17 Sep 2025

Exercise found to reduce artery hardening after weight loss in adults with obesity

Maintaining weight loss with regular exercise rather than the glucagon-like peptide-1 receptor agonist (GLP-1RA) liraglutide, a drug used to treat type 2 diabetes and obesity, seems to reduce atherosclerosis development in adults with obesity-a leading underlying cause of cardiovascular disease.

17 Sep 2025

Higher-dose semaglutide helps people lose nearly 19% of body weight

The STEP UP trial reveals semaglutide 7.2 mg significantly reduces weight compared to 2.4 mg, though it raises questions about gastrointestinal side effects.

16 Sep 2025

Cleveland Clinic study shows lasting benefits of weight-loss surgery over GLP-1 medicines

A large Cleveland Clinic study has found that people with obesity and type 2 diabetes who undergo weight-loss surgery live longer and face fewer serious health problems compared with those treated with GLP-1 receptor agonist medicines alone.

16 Sep 2025

Individuals taking semaglutide for weight loss experience less food noise than before

New research being presented at the Annual Meeting of the European Association for the Study of Diabetes (EASD) in Vienna, Austria (15-19 September) shows that individuals who are taking semaglutide for weight loss experience less food noise than before.

16 Sep 2025

Study: Half of adults without diabetes taking weight-loss drug discontinue treatment within a year

The new class of anti-obesity drugs, glucagon-like peptide-1 receptor agonists (GLP-1RAs), is proving remarkably effective at helping individuals lose weight.

15 Sep 2025

Genetic study shows dual GIPR/GLP1R action curbs binge alcohol use

Researchers used drug-target Mendelian randomization to test whether genetically proxied activation of GLP1R and GIPR influences alcohol-related behaviors. They found that GIPR, especially when combined with GLP1R, was linked to lower binge and heavy drinking, healthier food preferences, improved liver markers, and reduced coronary artery disease risk.

15 Sep 2025

Are GLP-1 drugs safe for women planning pregnancy?

A study reveals rising GLP-1 prescriptions in young women, highlighting low contraception use and potential risks for unintended pregnancies and fetal outcomes.

12 Sep 2025

Scientists uncover brain circuit that turns cravings into eating behavior

Researchers found that the bed nucleus of the stria terminalis integrates pleasure signals from central amygdala prodynorphin neurons and hunger signals from agouti-related peptide neurons to drive consumption. Manipulating this bed nucleus of the stria terminalis circuit bidirectionally altered food intake and body weight in mice.

11 Sep 2025

Experts warn tiny plastics in arteries may raise heart attack risk

Experts caution that nanoplastics and microplastics may constitute an emerging cardiovascular risk factor, with particles identified in arterial plaques associated with a 4.5-fold increase in major adverse cardiovascular events. Experimental evidence points to inflammation, oxidative stress, and vascular injury as key mechanisms.

10 Sep 2025

WHO expands essential medicines lists with new cancer and diabetes treatments

Today, the World Health Organization (WHO) has released updated editions of its Model Lists of Essential Medicines (EML) and Essential Medicines for Children (EMLc), adding new treatments for various types of cancer and for diabetes with associated comorbidities such as obesity.

5 Sep 2025

Longitudinal study reveals how GLP-2 analog therapy transforms the intestinal environment

Researchers from Japan discover that glucagon-like peptide-2 (GLP-2) analogs can deeply and beneficially reshape the intestinal environment.

27 Aug 2025

Glucagon News and Research

Study shows prediabetes remission does not always require weight loss

Scientists outline how future therapies could change type 1 diabetes care

New quintuple agonist shows promise for treating obesity and type 2 diabetes

Study points to a surprising new ally in the fight against type 2 diabetes

Can eating style affect how well GLP-1 drugs control diabetes and weight?

Daily orforglipron GLP-1 pill achieves over 11% weight loss in global obesity trial

Scientists unveil new obesity drug that reprograms fat and energy use

GLP-1RAs linked to lower risk of mortality and cardiovascular events in psoriasis patients

A new tool in the fight against obesity: Orforglipron's substantial weight loss results

Exercise found to reduce artery hardening after weight loss in adults with obesity

Higher-dose semaglutide helps people lose nearly 19% of body weight

Cleveland Clinic study shows lasting benefits of weight-loss surgery over GLP-1 medicines

Individuals taking semaglutide for weight loss experience less food noise than before

Study: Half of adults without diabetes taking weight-loss drug discontinue treatment within a year

Genetic study shows dual GIPR/GLP1R action curbs binge alcohol use

Are GLP-1 drugs safe for women planning pregnancy?

Scientists uncover brain circuit that turns cravings into eating behavior

Experts warn tiny plastics in arteries may raise heart attack risk

WHO expands essential medicines lists with new cancer and diabetes treatments

Longitudinal study reveals how GLP-2 analog therapy transforms the intestinal environment

Industry Focus eBook - Analytical Chemistry (2nd Edition) eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News